Brutons Tyrosine Kinase Btk Inhibitors Competitive Landscape Pipeline And Market Analysis

"Bruton's Tyrosine Kinase (BTK) Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2018", report provides comprehensive insights about marketed and pipeline drugs across this mechanism of action. The report provides the detailed analysis of 30+ products along with 25+ companies involved. Acerta Pharma and BeiGene are developing therapeutic drugs in the higher phase and Acerta Pharma has been granted both Orphan and Breakthrough Therapy Designation from FDA.

Products covered by Phase

  • Filed, Phase III, Phase II and Phase I
  • IND and Pre-clinical

Overview of pipeline development activities for Bruton's Tyrosine Kinase (BTK) Inhibitors

Pipeline analysis of 30+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.

Therapeutic segmentation of products for Bruton's Tyrosine Kinase (BTK) Inhibitors

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy.


Methodology

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.


Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope

  • The report provides competitive pipeline landscape of Bruton's Tyrosine Kinase (BTK) Inhibitors
  • The report provides the marketed drugs information including its sales, development activities and details of patent expiry
  • The report provides the insight of current and future market for Bruton's Tyrosine Kinase (BTK) Inhibitors
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Bruton's Tyrosine Kinase (BTK) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Bruton's Tyrosine Kinase (BTK) Inhibitors and also provide company profiling
  • Pipeline products coverage based on various stages of development ranging from late stage till pre-clinical stage
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to Buy

  • Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
  • Establish a comprehensive understanding of the current pipeline scenario Bruton's Tyrosine Kinase (BTK) Inhibitors to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Bruton's Tyrosine Kinase (BTK) Inhibitors R&D
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
  • Devise corrective measures for pipeline projects by understanding Bruton's Tyrosine Kinase (BTK) Inhibitors pipeline depth and focus of target therapeutics
  • Developing strategic initiatives to support your drug development activities
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Bruton's Tyrosine Kinase (BTK) Inhibitors to enhance and expand business potential and scope
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs
  • • Gaining a full picture of the Competitive Landscape for Evidence based Decisions


Report Highlights

Executive Summary

Collaborations

Technology

Overview

Structure of Bruton’s Tyrosine Kinase

Mechanism of Action

Expression of BTK

BTK Mutations

Bruton’s Tyrosine Kinase Inhibitor

BTK Inhibitors Role in Oncology

BTK Inhibitors Role in Autoimmune Diseases

Competitive Landscape – Active Drugs

Marketed and Pipeline Drugs

Marketed Drugs

Imbruvica: Janssen

Product Description

Research and Development

Product Development Activities

Drug Sales

Imbruvica – Heat Map

Analyst Insights: Imbruvica

Competitive landscape for Imbruvica

Sales of Imbruvica

Clinical Future of Imbruvica

BTK Inhibitors Market Evolution

BTK Inhibitors Class Share Evolution

Pipeline Therapeutics (Active Products)

Comparative Analysis

Late Stage Products (Filed & Phase III)

Comparative Analysis

ACP-196: Acerta Pharma

Product Description

Research and Development

Product Development Activities

Drug Sales

(The list continues)

Mid Stage Products (Phase II)

Comparative Analysis

Early Stage Products (Phase I and IND)

Comparative Analysis

Pre-clinical Stage Products

Comparative Analysis

Therapeutic Assessment: Active Products

Assessment by Monotherapy Products

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Stage and Molecule Type

Inactive Products

Other Inactive Products

Gist of BTK Inhibitors

List of Product

List of companies

Appendix

Table 1: Marketed and Pipeline BTK Inhibitors

Table 2: Total Products for BTK Inhibitors

Table 3: Late Stage Products (Phase III)

Table 4: Mid Stage Products (Phase II)

Table 5: Early Stage Products (Phase I and IND)

Table 6: Pre-clinical Stage Products

Table 7: Assessment by Monotherapy Products

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Stage and Molecule Type

Table 11: List of Dormant Products

Table 12: Other Inactive Products

Figure 1: Structure of Bruton’s Tyrosine Kinase

Figure 2: Involvement of BTK in B cell receptor signaling

Figure 3: Marketed and Pipeline BTK Inhibitors

Figure 4: Market Evolution (2013-2022)

Figure 5: Total Products for BTK Inhibitors

Figure 6: Late Stage Products (Filed & Phase III)

Figure 7: Mid Stage Products (Phase II)

Figure 8: Early Stage Products (Phase I and IND)

Figure 9: Pre-clinical Stage Products

Figure 10: Assessment by Monotherapy Products

Figure 11: Assessment by Route of Administration

Figure 12: Assessment by Stage and Route of Administration

Figure 13: Assessment by Stage and Molecule Type

AbbVie

ACEA Biosciences

Acerta Pharma

Aptose Biosciences

ArQule

BeiGene

Biogen

Bristol- Myers Squibb

Carna Biosciences

Celgene Corporation

Eternity Bioscience

Gilead Sciences

Hanmi Pharmaceutical

KBP Biosciences

Loxo Oncology

LSK BioPharma

Merck

Ono Pharmaceutical

Pharmacyclics

Principia Biopharma

Roche

Sunesis

Takeda

Tolero

X-Rx

Zhejiang DTRM Biopharma

  • Tags:
  • Bruton's Tyrosine Kinase (BTK) Inhi...
  • Pipeline and Market Analysis
  • 2018

Forward to Friend

Need A Quote